Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks  from a “acquire” ranking to a “hold” ranking in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It focuses on finding and also establishing small particle drug prospects to treat cancer cells. The Business‘s products under various stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts additionally recently talked about the company. Noble Financial editioned a “get” score as well as issued a $11.00 cost purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and set a “purchase” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving average rate of $2.90 and also a two-hundred day relocating typical cost of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as an adverse internet margin of 8,294.27%. The company had profits of $0.06 million during the quarter, contrasted to the consensus quote of $0.06 million. During the exact same quarter in the previous year, the firm published ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will post -1.18 EPS for the existing year.

A number of hedge funds have actually just recently bought and sold shares of ONTX. GSA Resources Partners LLP bought a brand-new setting in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Lastly, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also other institutional investors own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the recognition as well as growth of oncology therapeutics. It focuses on uncovering and also developing small particle medicine prospects to deal with cancer. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more details about research offerings from Zacks Investment Research, visit Zacks.com.

This immediate information alert was created by narrative science technology and monetary data from Market in order to give visitors with the fastest as well as most accurate coverage. This tale was examined by Market’s editorial group before publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Before you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s top-rated as well as ideal performing research analysts as well as the stocks they recommend to their clients every day. Market has actually recognized the five stocks that top experts are silently murmuring to their clients to get currently before the broader market catches on … as well as Onconova Therapeutics had not been on the checklist.

While Onconova Therapeutics presently has a “Buy” ranking amongst experts, top-rated experts believe these five stocks are much better buys.